The ELITE series merges artificial intelligence and augmented processing capabilities.
SonoScape Medical has launched its latest ultrasound system – the ELITE series, the company announced this week.
By combining artificial intelligence (AI) solutions and greater processing capabilities, the system is designed to improve diagnostic capabilities, company officials said.
“We developed the ELITE series in intensive cooperation with clinical experts,” said Zhou Wenping, head of research and development at SonoScape Medical. “I believe that this new series will substantially increase diagnostic confidence and empower clinicians to take advantage of the next level technologies, such as CEUS.”
SonoScape ELITE Courtesy: SonoScape Medical Corporation
This system adds AI-based automated tools, such as S-Fetus, Auto OB and lucid imaging technologies, as standard features on SonoScape’s Wis+ intelligent ultrasound platform. According to company details, the system offers four times the data processing capability and 10 times the system response rate of previous system iterations. In addition, it features advanced rendering models, including S-Live Silhouette and Color 3D.
The focus, officials said, is on optimizing image acquisition and diagnostic patient management workflows to help hospitals and clinics improve their performance, the experiences of their patients and staff, and health outcomes, while lowering the cost of care.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.